Comparison of proactive and usual approaches to offering predictive testing for BRCA1/2 mutations in unaffected relatives.
AffiliationAcademic Unit, Medical Genetics and Regional Genetics Service, St Mary's Hospital, Manchester, UK. email@example.com
MetadataShow full item record
AbstractThere have been few studies addressing uptake of predictive testing for BRCA1/2, only one comparing a proactive with usual family networking approach to dissemination. We report uptake of predictive genetic testing after directly offering BRCA1 presymptomatic genetic testing to 100 individuals in two generations of 5 large BRCA1 families compared with service testing of 196 families since that time. Uptake was significantly higher in the first generation (group 1), who were directly offered testing, and much higher in females. Seventy-four percent of unaffected women in the first generation proceeded to testing, 42% of men. This decreased to 44% of women in the second generation (group 2) and 9% males (p = 0.0003). Uptake in unaffected individuals in the final group (group 3) with no proactive approach was significantly lower than that in the first group. Overall uptake after 10 years was 56% (95% confidence interval, CI, 50-62%) for group 1 and 36% (95% CI 34.3-37.7%) for 1084 group 3 individuals (p = 0.0003). Among women, uptake was 74% (95% CI 67-81%) in group 1 at 10 years compared with 51.5% (95% CI 49-54%) in 552 group 3 women (p = 0.023). In men, uptake was 42% (95% CI 33-52%) in group 1 and 21.1% (95% CI 18.1-23.1%) among 532 men in group 3 (p = 0.0098). Although these results are not from a randomized trial, they show particularly among men a substantially higher uptake of genetic services with a direct approach. Importance should be given to more proactive approaches to ensure that men in BRCA1/2-positive families receive the appropriate information.
CitationComparison of proactive and usual approaches to offering predictive testing for BRCA1/2 mutations in unaffected relatives. 2009, 75 (2):124-32 Clin. Genet.
- Breast cancer risks in individuals testing negative for a known family mutation in BRCA1 or BRCA2.
- Authors: Domchek SM, Gaudet MM, Stopfer JE, Fleischaut MH, Powers J, Kauff N, Offit K, Nathanson KL, Robson M
- Issue date: 2010 Jan
- Uptake of testing for BRCA1/2 mutations in South East Scotland.
- Authors: Holloway SM, Bernhard B, Campbell H, Lam WW
- Issue date: 2008 Aug
- Men at risk of being a mutation carrier for hereditary breast/ovarian cancer: an exploration of attitudes and psychological functioning during genetic testing.
- Authors: Lodder L, Frets PG, Trijsburg RW, Tibben A, Meijers-Heijboer EJ, Duivenvoorden HJ, Wagner A, van Der Meer CA, Devilee P, Cornelisse CJ, Niermeijer MF
- Issue date: 2001 Jul
- Model-based predictions of BRCA1/2 mutation status in breast carcinoma patients treated at an academic medical center.
- Authors: Shannon KM, Lubratovich ML, Finkelstein DM, Smith BL, Powell SN, Seiden MV
- Issue date: 2002 Jan 15
- Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers.
- Authors: Graeser MK, Engel C, Rhiem K, Gadzicki D, Bick U, Kast K, Froster UG, Schlehe B, Bechtold A, Arnold N, Preisler-Adams S, Nestle-Kraemling C, Zaino M, Loeffler M, Kiechle M, Meindl A, Varga D, Schmutzler RK
- Issue date: 2009 Dec 10